Unit 3 backward integration plant ready for validation in Q1 FY27
The new block for contrast media intermediates is nearing completion and expected to be ready for qualification in Q1 FY27, improving cost competitiveness.
BLUEJETHEALTHCARE / guidance tracker
Keep management guidance in view.
Blue Jet Healthcare · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
expansion
Visakhapatnam greenfield capex of ₹1,000 crore over 3-4 years
Board-approved ₹1,000 crore investment for a greenfield site, with phase one dedicated to API and intermediates aligned with customer demand.
Hyderabad R&D center operational from Q3 FY27
Lease secured for R&D activities in Hyderabad; development work expected to commence from Q3 FY27, focusing on GLP-1 intermediates, peptide chemistry, and biocatalysis.
New artificial sweetener exhibit batches in FY27
Exhibit batches of a new artificial sweetener will be initiated in FY27, complementing the existing high-intensity sweetener portfolio.